/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

KEROS THERAPEUTICS INC

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$18.1 0.0755(7.55%) KROS at 04 Dec 2025 04:36 PM Biotechnology
Lowest Today 16.96
Highest Today 18.425
Today’s Open 16.96
Prev. Close 16.83
52 Week High 72.37
52 Week Low 9.12
Day’s Range: Low 16.96 High 18.425
52-Week Range: Low 9.12 High 72.37
1 day return -
1 Week return +3.45
1 month return +16.47
3 month return +16.21
6 month return +21.85
1 year return -73.31
3 year return -63.76
5 year return -76.37
10 year return -

Institutional Holdings

ADAR1 Capital Management LLC 13.27

BlackRock Inc 6.73

Madison Avenue Partners, LP 6.63

Vanguard Group Inc 6.48

Logos Global Management LP 4.92

Nantahala Capital Management, LLC 3.99

Western Standard LLC 3.78

TANG CAPITAL MANAGEMENT LLC 3.49

State Street Corp 3.41

D. E. Shaw & Co LP 3.19

Vanguard Total Stock Mkt Idx Inv 2.63

Orbimed Advisors, LLC 2.51

Goldman Sachs Group Inc 2.18

Morgan Stanley - Brokerage Accounts 2.16

Alkeon Capital Management, LLC 2.09

Geode Capital Management, LLC 2.04

iShares Russell 2000 ETF 2.03

SPDR® S&P Biotech ETF 1.63

Federated Hermes Inc 1.61

Redmile Group, LLC 1.36

Jacobs Levy Equity Management, Inc. 1.29

HHG PLC 1.16

Vanguard Explorer Inv 1.12

Federated Hermes MDT SCC Institutional 1.11

Federated Hermes MDT Small Cap Core IS 1.11

ACAP Strategic A 1.03

Vanguard Institutional Extnd Mkt Idx Tr 0.94

Fidelity Small Cap Index 0.84

PDT Partners, LLC 0.82

iShares Russell 2000 Value ETF 0.74

GS Glb Sm Cp CORE Eq Base Inc USD Close 0.64

iShares Biotechnology ETF 0.50

Xtrackers Stoxx Global Div100 Swp ETF 1D 0.48

Fidelity Extended Market Index 0.46

Schwab US Small-Cap ETF™ 0.41

Multi-Manager Small Cap Eq Strat Inst 0.41

Federated Hermes MDT SCG Institutional 0.40

Federated Hermes MDT Small Cap Growth IS 0.40

Vanguard Russell 2000 ETF 0.40

Fidelity Select Biotechnology 0.32

Market Status

Strong Buy: 5

Buy: 2

Hold: 6

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 512.74 M

PB Ratio 0.7569

PE Ratio 11.0

Enterprise Value -143.50 M

Total Assets 615.89 M

Volume 2152210

Company Financials

Annual Revenue FY24:3550000 3.6M, FY23:151000 0.2M, FY22:0 0.0M, FY21:20100000 20.1M, FY20:0 0.0M

Annual Profit FY24:3550000 3.6M, FY23:-664000 -0.7M, FY22:null 0.0M, FY21:20100000 20.1M, FY20:null 0.0M

Annual Net worth FY24:-187353000 -187.4M, FY23:-152992000 -153.0M, FY22:-104680000 -104.7M, FY21:-58744000 -58.7M, FY20:-45361000 -45.4M

Quarterly Revenue Q3/2025:14262000 14.3M, Q2/2025:18168000 18.2M, Q1/2025:211246000 211.2M, Q3/2024:388000 0.4M, Q2/2024:37000 0.0M

Quarterly Profit Q3/2025:13867000 13.9M, Q2/2025:17798000 17.8M, Q1/2025:211246000 211.2M, Q3/2024:388000 0.4M, Q2/2024:-269000 -0.3M

Quarterly Net worth Q3/2025:-7280000 -7.3M, Q2/2025:-30696000 -30.7M, Q1/2025:148451000 148.5M, Q3/2024:-52956000 -53.0M, Q2/2024:-45257000 -45.3M

Fund house & investment objective

Company Information Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment neuromuscular diseases. The company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize elritercept and licensed products containing elritercept. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

Organisation Biotechnology

Employees 82

Industry Biotechnology

CEO Dr. Jasbir S. Seehra Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow